Cargando…
In Well‐Treated Celiac Patients Low‐Level Mucosal Inflammation Predicts Response to 14‐day Gluten Challenge
In celiac disease (CeD), gluten activates adaptive immune cells that cause damage to the small intestinal mucosa. Histological evaluation of intestinal biopsies allows for grading of disease severity. CeD can effectively be treated with a life‐long gluten‐free diet. Gluten challenge of treated CeD p...
Autores principales: | Stamnaes, Jorunn, Stray, Daniel, Stensland, Maria, Sarna, Vikas K., Nyman, Tuula A., Lundin, Knut E. A., Sollid, Ludvig M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887593/ https://www.ncbi.nlm.nih.gov/pubmed/33643806 http://dx.doi.org/10.1002/advs.202003526 |
Ejemplares similares
-
TG2-gluten complexes as antigens for gluten-specific and transglutaminase-2 specific B cells in celiac disease
por: Lindstad, Christian B., et al.
Publicado: (2021) -
Transglutaminase 2 affinity and enzyme‐substrate intermediate stability as determining factors for T‐cell responses to gluten peptides in celiac disease
por: Amundsen, Sunniva F., et al.
Publicado: (2022) -
Expression of transglutaminase 2 in human gut epithelial cells: Implications for coeliac disease
por: Amundsen, Sunniva F., et al.
Publicado: (2023) -
Identification of gluten T cell epitopes driving celiac disease
por: Chlubnová, Markéta, et al.
Publicado: (2023) -
Injection of prototypic celiac anti-transglutaminase 2 antibodies in mice does not cause enteropathy
por: Lindstad, Christian B., et al.
Publicado: (2022)